- Clinical Effectiveness of TetracyclineClass Agents Based Regimens in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia: A Single-Center Retrospective Cohort Study
-
Kim SH, Wi YM, Peck KR
- KMID: 2545541
- J Korean Med Sci.
- 2023 Aug;38(34):e263.
- doi: 10.3346/jkms.2023.38.e263
This study evaluated the clinical outcome of carbapenem-resistant Acinetobacter baumannii (CRAB) bacteremia and the clinical effectiveness of tetracyclines-based therapy. In a retrospective cohort study over 5 years period, 108 patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics and Risk Factors for Mortality in Critical COVID-19 Patients Aged 50 Years or Younger During Omicron Wave in Korea: Comparison With Patients Older Than 50 Years of Age
-
Shi HJ, Yang J, Eom JS, Ko JH, Peck KR, Kim UJ, Jung SI, Kim S, Seok H, Hyun M, Kim HA, Kim B, Joo EJ, Cheong HS, Jun CH, Wi YM, Kim J, Kym S, Lim S, Park Y
- KMID: 2544476
- J Korean Med Sci.
- 2023 Jul;38(28):e217.
- doi: 10.3346/jkms.2023.38.e217
Background: The coronavirus disease 2019 (COVID-19) pandemic has caused the death of thousands of patients worldwide. Although age is known to be a risk factor for morbidity and mortality in... -
- CITED
-
- Close
- SHARE
-
- Close
- Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
-
Yang J, Hyeon S, Baek JY, Kang MS, Lee KY, Lee YH, Huh K, Cho SY, Kang CI, Chung DR, Peck KR, Won G, Lee HW, Kim K, Hwang I, Lee SY, Kim BC, Lee Yk, Ko JH
- KMID: 2544411
- J Korean Med Sci.
- 2023 Jul;38(27):e205.
- doi: 10.3346/jkms.2023.38.e205
Tixagevimab/cilgavimab is a monoclonal antibody used to prevent coronavirus disease 2019 among immunocompromised hosts and maintained neutralizing activity against early omicron variants. Omicron BN.1 became a dominant circulating strain in... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Features and Outcomes of Invasive Fusariosis: A Case Series in a Single Center with Literature Review
-
Kim JY, Kang CI, Lee JH, Lee WJ, Huh K, Cho SY, Chung DR, Peck KR
- KMID: 2544449
- Infect Chemother.
- 2023 Jun;55(2):290-294.
- doi: 10.3947/ic.2018.0717
Fusarium species, which are commonly found in soil, water, and organic substrates, can cause serious infections especially in immunocompromised patients. Fusarium infection is notoriously difficult to treat, because of their... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical effectiveness of live attenuated herpes zoster vaccine in kidney transplant recipients immunized prior to kidney transplantation: a retrospective single-center cohort study
-
Kim SH, Huh K, Lee KW, Park JB, Huh WS, Ko JH, Peck KR
- KMID: 2535235
- Korean J Transplant.
- 2022 Nov;36(Supple 1):S369.
- doi: 10.4285/ATW2022.F-5089
Background: Kidney transplant recipients have an increased risk of herpes zoster (HZ) and its complications. Although live attenuated or recombinant subunit zoster vaccine has been recommended for candidates for kidney... -
- CITED
-
- Close
- SHARE
-
- Close
- Acute Disseminated Pneumococcal Infection with Meningitis and Septic Arthritis Caused by Extensively Drug-resistant Streptococcus pneumoniae
-
Shi HJ, Baek JY, Chung DR, Kim K, Peck KR, Kang CI
- KMID: 2530831
- Korean J healthc assoc Infect Control Prev.
- 2022 Jun;27(1):80-84.
- doi: 10.14192/kjicp.2022.27.1.80
The emergence and spread of antimicrobial resistance threatens the successful treatment of invasive pneumococcal disease (IPD). We report a case of disseminated pneumococcal infection with meningitis, spondylitis, and septic arthritis... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics and Risk Factors for Mortality in Critical Coronavirus Disease 2019 Patients 50 Years of Age or Younger During the Delta Wave: Comparison With Patients > 50 Years in Korea
-
Shi HJ, Nham E, Kim B, Joo EJ, Cheong HS, Hong SH, Hyun M, Kim Ha, Jang S, Rhee JY, Kim J, Kim S, Cho HK, Wi YM, Cheon S, Kim YS, Lim S, Seok H, Jung SI, Eom JS, Peck KR
- KMID: 2530417
- J Korean Med Sci.
- 2022 Jun;37(22):e175.
- doi: 10.3346/jkms.2022.37.e175
Background: Numerous patients around the globe are dying from coronavirus disease 2019 (COVID-19). While age is a known risk factor, risk analysis in the young generation is lacking. The present... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study
-
Kim SH, Hong JY, Bae S, Lee H, Wi YM, Ko JH, Kim B, Joo EJ, Seok H, Shi HJ, Yoo JR, Hyun M, Kim Ha, Jang S, Mun SJ, Kim J, Kim MC, Jung DS, Kim SH, Peck KR
- KMID: 2529708
- J Korean Med Sci.
- 2022 May;37(18):e134.
- doi: 10.3346/jkms.2022.37.e134
Background: Coronavirus disease 2019 (COVID-19) is often accompanied by secondary infections, such as invasive aspergillosis. In this study, risk factors for developing COVID-19-associated pulmonary aspergillosis (CAPA) and their clinical outcomes... -
- CITED
-
- Close
- SHARE
-
- Close
- Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
-
Hong JY, Ko JH, Yang J, Ha S, Nham E, Huh K, Cho SY, Kang CI, Chung DR, Baek JY, Sohn YM, Park HJ, Lee B, Huh HJ, Kang ES, Suh GY, Chung CR, Peck KR
- KMID: 2529388
- Yonsei Med J.
- 2022 May;63(5):430-439.
- doi: 10.3349/ymj.2022.63.5.430
Purpose: Real-world experience with tocilizumab in combination with dexamethasone in patients with severe coronavirus disease (COVID-19) needs to be investigated. Materials and Methods: A retrospective cohort study was conducted to evaluate... -
- CITED
-
- Close
- SHARE
-
- Close
- An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward
-
Wi YM, Kim SH, Peck KR
- KMID: 2525009
- J Korean Med Sci.
- 2022 Jan;37(4):e28.
- doi: 10.3346/jkms.2022.37.e28
Background: A rapid decline in immunity and low neutralizing activity against the delta variant in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinees has been observed. This study describes an... -
- CITED
-
- Close
- SHARE
-
- Close
- Seroprevalence of SARS-CoV-2 antibodies during the third wave of COVID-19 in the Seoul metropolitan area of Korea
-
Yoon K, Kim J, Peck KR, Kim HS, Lee H, Hwang YS, Lee SY, Cho Si, Lee HJ, Kim Yg, Kim B, Lee JW, Kim AR, Do HN, Kim DH
- KMID: 2541348
- Epidemiol Health.
- 2022;44(1):e2022085.
- doi: 10.4178/epih.e2022085
OBJECTIVES: After the third wave of coronavirus disease 2019 (COVID-19), by mid-February 2021, approximately 0.16% of the Korean population was confirmed positive, which appeared to be among the lowest rates... -
- CITED
-
- Close
- SHARE
-
- Close
- Monkeypox: the resurgence of forgotten things
-
Kim SB, Jung J, Peck KR
- KMID: 2541708
- Epidemiol Health.
- 2022;44(1):e2022082.
- doi: 10.4178/epih.e2022082
Monkeypox, a rare zoonotic disease, is primarily prevalent in Central and Western Africa. However, monkeypox is emerging as a worldwide concern due to the 2022 monkeypox outbreak, which is the... -
- CITED
-
- Close
- SHARE
-
- Close
- Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea
-
Jo Y, Kim SB, Radnaabaatar M, Huh K, Yoo JH, Peck KR, Park H, Jung J
- KMID: 2531850
- Epidemiol Health.
- 2022;44(1):e2022034.
- doi: 10.4178/epih.e2022034
OBJECTIVES: Many countries have authorized the emergency use of oral antiviral agents for patients with mild-to-moderate cases of coronavirus disease 2019 (COVID-19). We assessed the cost-effectiveness of these agents for... -
- CITED
-
- Close
- SHARE
-
- Close
- National Academy of Medicine of Korea (NAMOK) Key Statements on COVID-19
-
Shin HS, Park H, Kwon JS, Namgoong H, Kim SJ, Kim JM, Peck KR, Lee K, Lee Jk, Lee J, Han HC, Hong S, Park BJ, Lim TH, Hwang ES, Woo JH, NAMOK COVID-19 Committee
- KMID: 2521468
- J Korean Med Sci.
- 2021 Oct;36(41):e287.
- doi: 10.3346/jkms.2021.36.e287
-
- CITED
-
- Close
- SHARE
-
- Close
- Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine
-
Huh K, Na Y, Kim YE, Radnaabaatar M, Peck KR, Jung J
- KMID: 2518355
- J Korean Med Sci.
- 2021 Jul;36(27):e197.
- doi: 10.3346/jkms.2021.36.e197
We used the nationwide claims database to calculate the incidence of thrombotic events and predict their overall 2-week incidence. From 2006 to 2020, the incidence of deep vein thrombosis (DVT),... -
- CITED
-
- Close
- SHARE
-
- Close
- Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARSCoV-2 Monoclonal Antibody Treatment of Patients with COVID-19
-
Kim SB, Kim J, Huh K, Choi WS, Kim YJ, Joo EJ, Kim YJ, Yoon YK, Heo JY, Seo YB, Jeong SJ, Yu SY, Peck KR, Choi M, Yeom JS, Korean Society of Infectious Diseases (KSID)
- KMID: 2517472
- Infect Chemother.
- 2021 Jun;53(2):395-403.
- doi: 10.3947/ic.2021.0304
Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food... -
- CITED
-
- Close
- SHARE
-
- Close
- Developing a Framework for Pandemic COVID-19 Vaccine Allocation: a Modified Delphi Consensus Study in Korea
-
Choi MJ, Choi WS, Seong H, Choi JY, Kim JH, Kim YJ, Cho EY, Kim DH, Park H, Lee H, Kim NJ, Song JY, Cheong HJ, Kim SI, Peck KR
- KMID: 2516680
- J Korean Med Sci.
- 2021 Jun;36(23):e166.
- doi: 10.3346/jkms.2021.36.e166
Background: This study presents a framework for determining the allocation and distribution of the limited amount of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods: After analyzing the pandemic... -
- CITED
-
- Close
- SHARE
-
- Close
- Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience
-
Kim SH, Wi YM, Yun SY, Ryu JS, Shin JM, Lee EH, Seo KH, Lee SH, Peck KR
- KMID: 2514898
- J Korean Med Sci.
- 2021 Apr;36(14):e107.
- doi: 10.3346/jkms.2021.36.e107
Coronavirus disease 2019 vaccinations for healthcare workers (HCWs) have begun in South Korea. To investigate adverse events (AEs) of the first dose of each vaccine, any symptom was collected daily... -
- CITED
-
- Close
- SHARE
-
- Close
- Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19
-
Kim SB, Ryoo S, Huh K, Joo EJ, Kim YJ, Choi WS, Kim YJ, Yoon YK, Heo JY, Seo YB, Jeong SJ, Park Da, Yu SY, Lee HJ, Kim J, Jin Y, Park J, Peck KR, Choi M, Yeom JS, D
- KMID: 2514847
- Infect Chemother.
- 2021 Mar;53(1):166-219.
- doi: 10.3947/ic.2021.0303
Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study
-
Joo EJ, Ko JH, Kim SE, Kang SJ, Baek JH, Heo EY, Shi HJ, Eom JS, Choe PG, Bae S, Ra SH, Kim DY, Kim BN, Kang YM, Kim JY, Chung JW, Chang HH, Bae S, Cheon S, Park Y, Choi H, Lee E, Lee By, Park JW, Sohn Y, Heo JY, Kim SH, Peck KR
- KMID: 2514055
- J Korean Med Sci.
- 2021 Mar;36(11):e83.
- doi: 10.3346/jkms.2021.36.e83
Background: Remdesivir is widely used for the treatment of coronavirus disease 2019 (COVID-19), but controversies regarding its efficacy still remain. Methods: A retrospective cohort study was conducted to evaluate the effect... -
- CITED
-
- Close
- SHARE
-
- Close
